
|Articles|November 5, 2012
FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE
FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Strategies to Drive Pharmacy Sustainability in a Changing Landscape
3
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
4
Machine Learning Can Identify Immune Markers for Better Pneumococcal Vaccines
5



































